NEW RARE BLOG IS OUT NOW! How do you build a European biotech presence from the ground up? For Matthias Hess, it starts with purpose, precision, and the right people. In the latest edition of RARE, Laura Hulley, Principal Consultant at SciPro, speaks with Matthias Hess, Senior Vice President and Head of Europe at SpringWorks Therapeutics, about his transition from big pharma to rare disease leadership, and what it takes to deliver life-changing treatments across complex European markets. With SpringWorks expanding its reach and preparing for multiple EU launches, Matthias shares lessons in strategy, agility, and building with intention. Tune in for insight into: 🏥 Why rare tumors demand a precision-first approach 📍 How Switzerland became the ideal launchpad for growth 💡 What it takes to lead with vision in a fast-moving landscape Head to the our website to read the full blog and watch the episode now: https://lnkd.in/dfvDu5cd #RareTumors #PrecisionMedicine #Biotech
How to build a European biotech presence: Insights from SpringWorks Therapeutics
This title was summarized by AI from the post below.
More Relevant Posts
-
Tubulis GmbH Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline. Tubulis, reimagining antibody drug conjugates, led by Dr. Dominik Schumacher, Dr. Jonas Helma-Smets, Dr. Ingo Lehrke, Dr. Günter Fingerle-Rowson, MD, Dr. Bjoern M Hock, Dr. Matthew Norkunas, M.D., and others, has secured €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, FundPlus, HTGF | High-Tech Gründerfonds, OCCIDENT, and Seventure Partners. As part of the financing, Dr. Lorence Kim of Ascenta Capital and Patrick Heron of Frazier Life Sciences will join Tubulis’ Supervisory Board. Read More At: https://lnkd.in/deUeDUap X: https://lnkd.in/d2dCDrY7 Source: https://lnkd.in/eHd33H7b
-
-
Tubulis GmbH Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline. Tubulis, reimagining antibody drug conjugates, led by Dr. Dominik Schumacher, Dr. Jonas Helma-Smets, Dr. Ingo Lehrke, Dr. Günter Fingerle-Rowson, MD, Dr. Bjoern M Hock, Dr. Matthew Norkunas, M.D., and others, has secured €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, FundPlus, HTGF | High-Tech Gründerfonds, OCCIDENT, and Seventure Partners. As part of the financing, Dr. Lorence Kim of Ascenta Capital and Patrick Heron of Frazier Life Sciences will join Tubulis’ Supervisory Board. Read More At: https://lnkd.in/dgTNmQgP X: https://lnkd.in/dKERM9EK Source: https://lnkd.in/dRHWYvCF
Tubulis GmbH Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline. Tubulis, reimagining antibody drug conjugates, led by Dr. Dominik Schumacher, Dr. Jonas Helma-Smets, Dr. Ingo Lehrke, Dr. Günter Fingerle-Rowson, MD, Dr. Bjoern M Hock, Dr. Matthew Norkunas, M.D., and others, has secured €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, FundPlus, HTGF | High-Tech Gründerfonds, OCCIDENT, and Seventure Partners. As part of the financing, Dr. Lorence Kim of Ascenta Capital and Patrick Heron of Frazier Life Sciences will join Tubulis’ Supervisory Board. Read More At: https://lnkd.in/deUeDUap X: https://lnkd.in/d2dCDrY7 Source: https://lnkd.in/eHd33H7b
-
-
Caption 💥 U.S. biotech shows signs of revival. Mirador Therapeutics has raised $400 million in Series B funding, marking one of the largest biotech fundraises of 2025. The company focuses on autoimmune and anti-inflammatory therapies, and this round comes at a critical moment when investor sentiment toward biotech has been subdued for much of the year. 📊 Why it matters: 🔹 Signals renewed investor confidence in the U.S. biotech market 🔹 Positions Mirador as a leader in immunology-focused innovation 🔹 Marks a strong comeback for late-stage private biotech funding 💬 Could this be the start of a biotech funding rebound after months of market slowdown? — ✨ At Life Science Insights 360 (by InCx Insights), we bring you the latest global breakthroughs, funding trends, and innovations shaping the future of life sciences and healthcare. #LifeScienceInsights360 #InCxInsights #Biotech #Pharma #DrugDevelopment #FundingNews #MiradorTherapeutics #LifeSciences #Innovation #HealthcareInvestment #AutoimmuneDisorders #Immunology #BiotechFunding #HealthcareInnovation #GlobalBiotech
-
-
SFBN Feed: Star gets $125M Series D as it begins Phase 3 in bleeding disorders https://lnkd.in/gTTaszBv Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
-
Proud to announce Gimv’s successful exit from ImCheck Therapeutics, acquired by Ipsen. This transaction is exemplary for our strategy of supporting breakthrough science and visionary teams in life sciences, creating #shareholder #value and #societal #benefits at the same time. Read the full press release in English 👉 https://bit.ly/4nfitWU in Dutch 👉 https://bit.ly/4ndL5jd #BuildingLeadingCompanies #LifeSciences #Impact #Innovation Bram Vanparys, PhD, MBA Rishabh Chawla Michaël Vlemmix Andreas Jurgeit Christoph Kocher Sandy Blin Ana Algueró Nadal, PhD Charlotte De Cort
-
-
CARB-X is live in London for the first day of the inaugural Global AMR Innovators Conference (GAMRIC)! This week, CARB-X and partners from around the world are gathering for in-depth discussions on the urgent need for innovation in therapeutics, diagnostics, and preventatives. AMR is a global crisis, and CARB-X committed to accelerating the science to solve it. #GAMRIC2025 #AMR #CARBX #GlobalHealth
-
Compact design. Big impact. For the team at Tridek-One Therapeutics, the MyGlo® Reagent Reader transformed their workflow—bringing reliable luminescence detection directly to the bench and enabling fast, cloud-connected data access through ProNect®. Read how this compact tool is accelerating discovery in immunomodulating research: https://bit.ly/4qDJ2rU
-
-
🎉 Excited to announce that SR One co-led the $205M Series A for Crystalys Therapeutics alongside Novo Holdings and Catalys Pacific Crystalys is advancing dotinurad, a next-generation gout therapy already approved and treating 1.2M+ patients across several countries in Asia, through global Phase 3 trials to address critical unmet needs in the US and Europe. Proud to support this experienced team led by James Mackay, Ph.D. as they bring better treatment options to patients. #Biotech #VentureCapital #SROne
-
AeroRx Therapeutics today announced the closing of a $21 million Series A financing led by Avalon BioVentures, with participation from Correlation Ventures, Alexandria Venture Investments, and others. Proceeds will support advancement of AERO-007, the first nebulized LABA/LAMA combination in development for chronic obstructive pulmonary disease (COPD), into late-stage clinical development. Positive Phase 2a study data showed that AERO-007 was well tolerated in patients with moderate to severe COPD, producing rapid-onset, clinically meaningful bronchodilation sustained through 24 hours at both low and high doses. With this financing, AeroRx is preparing to initiate a Phase 2b dose-optimization study and advance toward NDA-enabling development. Read the press release for more: https://lnkd.in/gyicyAqv #COPD #RespiratoryDisease #Biotech #Financing #DrugDelivery #ClinicalTrials
